NCT03936465已完成1 期
Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 (CC-90010) in Pediatric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 6
- 主要终点
- The Rate of Toxicities from Protocol Therapy
研究概览
简要总结
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain tumors or pediatric tumors that have spread to the brain.
详细描述
This is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved BMS-986158 or BMS-986378 as a treatment for any disease.
BMS-986158 and BMS-986378 are currently still being studied in adults. This is the first time that BMS-986158 or BMS-986378 will be evaluated in younger children, though children 12-17 years of age may also be included in parts of adult studies of BMS-986158.
Research in the laboratory has shown that BMS-986158 and BMS-986378 may have activity against cancer cells. These drugs belong to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≤ 21 years at time of enrollment. Note the requirement in section 3.1.6 that all patients must be able to swallow intact capsules.
- •Karnofsky performance status ≥ 50% for patients ≥16 years of age or Lansky ≥ 50% for patients <16 years of age (see Appendix A)
- •Diagnosis requirement
- •Participants must have evaluable or measurable disease (see Section 11).
- •Must have disease that is relapsed or refractory and for which standard curative measures do not exist or are no longer effective.
- •For Arm 1, Cohort 1A, participants must have histologically confirmed non-CNS primary solid tumors or lymphoma based upon biopsy or surgery at relapse/progression. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
- •For Arm 1, Cohort 1B, participants must have histologically confirmed solid tumors or lymphoma based upon biopsy or surgery at relapse/progression as well as documentation of one of the following confirmed tumor molecular features obtained in a laboratory certified to return results for clinical purposes. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
- •MYCN amplification or high copy number gain
- •MYC amplification or high copy number gain
- •Translocation involving MYC or MYCN
- •Translocation involving BRD4 or BRD3
- •BRD4 amplification or high copy number gain
- •Histologic diagnosis of NUT midline carcinoma
- •For Arm 2, Cohort 2A, participants must have histologically confirmed primary CNS p tumors or untreated CNS metastases based upon biopsy or surgery at relapse/progression. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
- •For Arm 2, Cohort 2B, participants must have histologically confirmed primary CNS p tumors or untreated CNS metastases based upon biopsy or surgery at relapse/progression as well as documentation of one of the following confirmed tumor molecular features obtained in a laboratory certified to return results for clinical purposes. Patients without biopsy or surgery at relapse/progression and with tissue only available from initial diagnosis may still be considered after discussion with the overall Primary Investigator.
- •MYCN amplification or high copy number gain
- •MYC amplification or high copy number gain
- •Translocation involving MYC or MYCN
- •Translocation involving BRD4 or BRD3
- •BRD4 amplification or high copy number gain
- •Histologic diagnosis of NUT midline carcinoma
- •Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy except organ function as noted in Section 3.1.
- •Patients must meet the following minimum washout periods prior to enrollment:
- •Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days for nitrosourea or mitomycin C).
- •Radiotherapy:
- •At least 14 days after local XRT (small port, including cranial radiation);
- •At least 90 days must have elapsed after prior TBI, or if >50% radiation of pelvis;
- •At least 180 days must have elapsed after prior craniospinal XRT;
- •At least 42 days must have elapsed if other substantial BM radiation;
- •At least 42 days must have passed since last MIBG or other radionuclide therapy.
- •Small molecule biologic therapy: At least 7 days following the last dose of a small molecule biologic agent. For agents with known adverse events occurring beyond 7 days, this duration must be extended beyond the time in which adverse events are known to occur. If extended duration is required, this must be discussed with and approved by the overall PI.
- •Monoclonal antibody: At least 28 days must have elapsed after the last dose of therapeutic monoclonal antibody.
- •Myeloid growth factors: At least 14 days following the last dose of long-acting growth factor (e.g. Neulasta) or 7 days following short-acting growth factor.
- •Autologous hematopoietic stem cell transplant and stem cell boost: Patients must be at least 60 days from day 0 of an autologous stem cell transplant or autologous stem cell boost.
- •Cellular therapies (including CAR-T cells) and other non-cellular, non-antibody immunotherapies (e.g., vaccines): At least 42 days must have elapsed after last dose.
- •Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Major surgical procedure will be considered all surgical procedures aside from the following: Biopsy; central line placement/removal; bone marrow aspirate/biopsy; lumbar puncture; dental procedures; gastrostomy tube placement; and VP shunt placement/revision.
- •BET inhibitors: Patients must not have received prior treatment with a BET inhibitor, except patients with CNS tumors or CNS metastasis previously treated on Arm 1 of the trial who discontinued protocol therapy due to disease progression and not due to toxicity. Such patients may participate in Arm 2 of the trial.
- •Participants must have normal organ function as defined below.
- •Bone Marrow Function
- •For Patients without Documented Bone Marrow Involvement by Disease:
- •Hemoglobin > 8 g/dL (may be transfused)
- •Absolute neutrophil count ≥ 1,000 /uL
- •Platelets ≥ 100,000 /uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to CBC documenting eligibility.
- •For Patients with Documented Bone Marrow Involvement by Disease:
- •Hemoglobin > 8 g/dL (may be transfused)
- •Absolute neutrophil count ≥ 750 /uL
- •Platelets ≥ 75,000 /uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to CBC documenting eligibility.
- •Hepatic Function:
- •Total bilirubin ≤ 1.5 x upper limit of normal for age (patients with known Gilbert's may be considered after discussion with overall PI and if direct bilirubin is at or below the upper limit of normal for age)
- •ALT (SGPT) ≤ 3 x upper limit of normal (135 U/L) For the purpose of this study, the ULN for ALT is 45 U/L
- 另有 17 项未显示
排除标准
- •Prior solid organ or allogeneic stem cell transplantation.
- •Patients with primary or metastatic CNS tumors are not eligible for Arm 1, except:
- •-Patients with a history of CNS metastatic disease that has been resected and/or radiated without evidence of active CNS disease for 3 months preceding enrollment; NOTE: patients with primary CNS tumors or solid tumors with active CNS metastases will be eligible for Arm
- •Patients receiving any of the following prohibited foods and medications:
- •Agents listed in Appendix B within 7 days prior to enrollment
- •Grapefruit or Seville oranges and/or their juices within 7 days prior to enrollment
- •Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparins (unfractionated or low molecular weight heparin) at the time of enrollment. Note: Use of heparin to maintain patency of a central or peripheral catheter is allowed
- •Other investigational agents being administered under an IND.
- •Pregnant participants will not be entered on this study given that the effects of BMS-986158 and BMS-986378 (CC-90010) on the developing human fetus are unknown. Female participants of childbearing potential must have a documented negative pregnancy exam within 24 hours prior to dosing.
- •Breastfeeding mothers are not eligible, because there is an unknown risk for adverse events in nursing infants secondary to treatment of the mother with BMS-986158 or BMS-986378 (CC-90010).
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-986158 or BMS-986378 (CC-90010).
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients with a known history of HIV, hepatitis B, and/or hepatitis C (testing not required as part of screening).
- •Patients with gastrointestinal disease or disorder that could interfere with absorption of BMS-986158 or BMS-986378 (CC-90010), such as bowel obstruction or inflammatory bowel disease.
- •For Arm 1: Patients with BSA < 0.3 m2 for all dose levels except Dose Level -2 or -2i for which patients with BSA < 0.71 m2 will be excluded due to dose rounding constraints.
- •For Arm 2: Patients with BSA < 0.65 m2.
研究组 & 干预措施
Arm 1 Cohort A
Experimental
- Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
- Patients with unselected relapsed or refractory solid tumors or lymphoma
干预措施: BMS-986158 (Drug)
Arm 1 Cohort B
Experimental
- Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
- Patients with relapsed or refractory solid tumors or lymphoma that have defined molecular features predicted to increase sensitivity to BET inhibition
干预措施: BMS-986158 (Drug)
Arm 2 Cohort A
Experimental
- Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.
- Patients with relapsed or refractory CNS tumors or CNS metastatic tumors
干预措施: BMS-986378 (Drug)
Arm 2 Cohort B
Experimental
- Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.
- Patients with relapsed or refractory CNS tumors or CNS metastatic tumors that have defined molecular features predicted to increase sensitivity to BET inhibition
干预措施: BMS-986378 (Drug)
结局指标
主要结局
The Rate of Toxicities from Protocol Therapy
时间窗: 2 years
Adverse events coded using CTCAE version 5
Dose Limiting Toxicity Rate
时间窗: 28 days (first cycle)
Dose limiting toxicity as defined in protocol
次要结局
- Objective Response Rate(2 years)
- Blood Markers of Response(2 years)
- Pharmacodynamics of BMS-986158 (Arm 1) or BMS-986378 (Arm 2)(2 years)
- CSF Markers of Response(2 years)
- Pharmacokinetics of BMS-986158 (Arm 1) or BMS-986378 (Arm 2)(2 years)
- Tumor Markers of Response(2 years)
研究者
Steven DuBois, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Study of BMS-986158 in Subjects With Select Advanced CancersAdvanced TumorsNCT02419417Bristol-Myers Squibb83
撤回
1 期
A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult ParticipantsHealthy Adult VolunteersNCT06034899Bristol-Myers Squibb
终止
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial CancersCancerNCT03363776Bristol-Myers Squibb10
已完成
1 期
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsBroad Solid TumorNCT02913313Bristol-Myers Squibb101
终止
1 期
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid TumorsNeoplasmsCancerNCT02630251GlaxoSmithKline5